MYCB1 Group

About MYCB1 Group

MYCB1 Group operates at the intersection of pharmaceuticals and health technology, specializing in cannabinoid-based medical solutions. Founded in 2017 by Ernesto Diringuer, the Dutch company integrates pharmaceutical manufacturing, pharmacy operations, and software engineering to provide data-driven, personalized therapies. The founder's journey began with the goal of collecting scientifically useful real-world data from patients to demonstrate the efficacy of medicinal cannabis. This led to the development of MYCB1's proprietary platform, ALETTA.

The company's business model is multifaceted, serving patients, pharmacies, and other businesses within the healthcare sector. For patients and physicians, MYCB1 develops, produces, and distributes prescription-only, GMP-grade cannabinoid medications. Its subsidiary, MYCB1 GmbH, located in Steinheim, Germany, handles manufacturing and distribution for the German market, adhering to strict GMP (Good Manufacturing Practice) standards. The company also provides Contract Manufacturing Organization (CMO) and white-label services, enabling other businesses to market high-quality, cannabinoid-based prescription medications under their own brand without needing their own GMP-compliant facilities.

A core component of MYCB1's offering is the ALETTA platform, a tool designed to gather high-quality, real-world evidence from patients undergoing cannabinoid treatment. This platform, which utilizes generative AI, helps to address the lack of scientific evidence and personalization in the industry. Patients use an application to report outcomes through standardized, internationally recognized questionnaires, providing valuable data for treatment optimization and research. The product portfolio includes various full-spectrum cannabis extracts with different THC and CBD concentrations, produced using high-quality raw materials from established suppliers like Bedrocan. MYCB1 has secured certifications for its products and services in the Netherlands and Germany and is expanding through distribution agreements in Scandinavia and partnerships across Europe, Asia, and Latin America. In a significant milestone, the company signed a share subscription facility agreement for up to €30.8M with GEM Global Yield LLC in September 2023 to secure funding as it prepares for a public listing.